Biocompatibility Assistant Tool
Introduction to Biocompatibility
Biocompatibility is the ability of a medical device/material to perform as intended without unacceptable local or systemic adverse effects. It hinges on toxicology, immunology, inflammation, hemocompatibility, and degradation chemistry.
Why it matters
Non-biocompatible devices can harm patients, trigger recalls, and create regulatory/ legal exposure.
Regulatory anchors
- ISO 10993 series (-1, -5, -10, -11, -4, -18/-17, etc.)
- FDA: “Use of ISO 10993-1” guidance, risk-based alignment
- EU MDR: GSPR biocompatibility; similar alignment in JP/CA
Example
Polyurethane-covered breast implants (1980s) raised carcinogenicity concerns from degradation products → market withdrawal. Lesson: chemistry & degradation matter.
Decision Wizard (ISO 10993-1 style)
Answer a few questions; the assistant suggests a preliminary test matrix and documentation tasks. You can add items to your plan and tailor as needed.
Your Biocompatibility Plan
Review, edit, check off tasks, then export. A starter plan can be seeded from the wizard or the solved example below.
Items
| ✓ | Item | Type | Rationale |
|---|
Materials & Degradation
Selection principles
- Prefer materials with clinical history & published safety
- Understand additives, catalysts, residual monomers
- Surface chemistry often drives biological response
Degradation & by-products
- Map plausible degradation routes (hydrolysis, oxidation, wear/ion release)
- Characterize leachables/extractables (10993-18)
- Assess tolerable intake (10993-17)
Examples
Titanium (implants): excellent corrosion resistance, low ion release.
PEG hydrogels: generally non-toxic; watch residuals.
Polyurethane: versatile; watch for oxidative degradation products.
Quick-Reference Tables
Key Testing Types & Standards
| Test | Objective | Standard | Example |
|---|---|---|---|
| Cytotoxicity | Toxic to cells? | ISO 10993-5 | PEG hydrogel |
| Sensitization | Allergic response? | ISO 10993-10 | Adhesive |
| Irritation | Skin/mucosal irritation? | ISO 10993-10 | Glove material |
| Hemocompatibility | Blood interactions | ISO 10993-4 | Stent |
| Systemic toxicity | Systemic adverse effects | ISO 10993-11 | Drug-eluting |
| Chem. characterization | ID/quantify chemicals | ISO 10993-18 | All materials |
| Tox. risk assessment | Tolerable intakes | ISO 10993-17 | Leachables |
Material Selection Considerations
| Material | Properties | Common Use | Biocomp Considerations |
|---|---|---|---|
| PEG | Hydrophilic; gels | Hydrogels | Residual monomers |
| Polyurethane | Flexible | Films, catheters | Irritation potential |
| Silicone | Durable | Tubing, implants | Rare sensitization |
| Titanium | Corrosion-resistant | Implants | Low risk |
| Herbal extracts | Bioactive | Dressings | Allergy risk |
Risk Assessment & Mitigation
| Risk | Impact | Assessed via | Mitigation |
|---|---|---|---|
| Cytotoxicity | Cell damage | 10993-5 | Material selection; process controls |
| Sensitization | Allergy | 10993-10 | Limit allergens; alternatives |
| Irritation | Skin reaction | 10993-10 | Low-irritant materials; test on compromised skin |
| Systemic tox | Organ/system harm | 10993-11 | 10993-18/-17; dose control |
| Degradation | Toxic by-products | Degradation studies | Stabilizers; monitoring |
Documentation for Submissions
| Document | Content | Purpose | Example |
|---|---|---|---|
| Test Reports | Protocol, raw data, analysis | Evidence | Cytotox. report |
| Risk Assessment | Hazards, rationale, mitigations | Control risks | Sensit. rationale |
| Regulatory Dossier | All biocomp data | Submission | 510(k)/PMA |
| PMS Plan | Post-market monitoring | Continued safety | AE plan |
Case Studies
Polyurethane Breast Implants
Degradation raised carcinogenicity concerns → withdrawal.
Sulzer Hip Implants (2000)
Manufacturing residue drove adverse tissue reactions → loosening/failure.
Mini Quiz (6 Questions)
Instant feedback with explanations. Passing score: 80% (you’ll see your score below).
Documentation & Reporting
- Keep protocols, raw data, and signed reports for each test.
- Maintain a master Biological Evaluation Plan (BEP) and BER (Report).
- Map all materials, additives, processing aids, residues, packaging that may contact the body.
- Use chemical characterization to support test reduction with scientific rationale.
Notes & Disclaimers
- This assistant provides educational, preliminary recommendations aligned with ISO 10993 principles. It is not legal or regulatory advice.
- Final test selection must follow a documented risk-based process and device-specific considerations.
- For drug-device or novel technologies, expect additional endpoints (e.g., genotoxicity, carcinogenicity, implantation, chronic toxicity, pyrogenicity) based on risk.
